JP2016512551A5 - - Google Patents

Download PDF

Info

Publication number
JP2016512551A5
JP2016512551A5 JP2016501731A JP2016501731A JP2016512551A5 JP 2016512551 A5 JP2016512551 A5 JP 2016512551A5 JP 2016501731 A JP2016501731 A JP 2016501731A JP 2016501731 A JP2016501731 A JP 2016501731A JP 2016512551 A5 JP2016512551 A5 JP 2016512551A5
Authority
JP
Japan
Prior art keywords
seq
antibody
cdr
heavy chain
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016501731A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512551A (ja
JP6674888B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/025044 external-priority patent/WO2014165271A2/en
Publication of JP2016512551A publication Critical patent/JP2016512551A/ja
Publication of JP2016512551A5 publication Critical patent/JP2016512551A5/ja
Application granted granted Critical
Publication of JP6674888B2 publication Critical patent/JP6674888B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016501731A 2013-03-13 2014-03-12 タウ免疫療法 Active JP6674888B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361780624P 2013-03-13 2013-03-13
US61/780,624 2013-03-13
US201361800382P 2013-03-15 2013-03-15
US61/800,382 2013-03-15
PCT/US2014/025044 WO2014165271A2 (en) 2013-03-13 2014-03-12 Tau immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020039557A Division JP7044399B2 (ja) 2013-03-13 2020-03-09 タウ免疫療法

Publications (3)

Publication Number Publication Date
JP2016512551A JP2016512551A (ja) 2016-04-28
JP2016512551A5 true JP2016512551A5 (OSRAM) 2017-04-06
JP6674888B2 JP6674888B2 (ja) 2020-04-01

Family

ID=51659327

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016501731A Active JP6674888B2 (ja) 2013-03-13 2014-03-12 タウ免疫療法
JP2020039557A Active JP7044399B2 (ja) 2013-03-13 2020-03-09 タウ免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020039557A Active JP7044399B2 (ja) 2013-03-13 2020-03-09 タウ免疫療法

Country Status (19)

Country Link
US (3) US10501531B2 (OSRAM)
EP (2) EP3689904A1 (OSRAM)
JP (2) JP6674888B2 (OSRAM)
KR (1) KR102313513B1 (OSRAM)
CN (1) CN105121465B (OSRAM)
AU (2) AU2014248515B2 (OSRAM)
BR (1) BR112015022260B1 (OSRAM)
CA (1) CA2902026C (OSRAM)
CU (1) CU24446B1 (OSRAM)
EA (1) EA035943B1 (OSRAM)
ES (1) ES2766762T3 (OSRAM)
IL (1) IL241124B (OSRAM)
MX (2) MX375354B (OSRAM)
PE (1) PE20152004A1 (OSRAM)
PH (1) PH12015501926A1 (OSRAM)
SA (1) SA515361031B1 (OSRAM)
SG (2) SG10201707855YA (OSRAM)
WO (1) WO2014165271A2 (OSRAM)
ZA (1) ZA201507464B (OSRAM)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014008404A1 (en) 2012-07-03 2014-01-09 Washington University Antibodies to tau
JP6674888B2 (ja) 2013-03-13 2020-04-01 プロセナ バイオサイエンシーズ リミテッド タウ免疫療法
KR101791296B1 (ko) * 2014-04-17 2017-10-27 제주대학교 산학협력단 알츠하이머병 관련 돌연변이 유전자를 포함하는 발현 카세트, 벡터, 및 이를 이용하여 형질전환된 세포주
TW202136296A (zh) 2014-06-27 2021-10-01 美商C2N醫療診斷有限責任公司 人類化抗-tau抗體
WO2016137950A1 (en) * 2015-02-24 2016-09-01 Rpeptide, Llc Anti-tau antibodies
TWI669314B (zh) 2015-02-26 2019-08-21 美國禮來大藥廠 針對tau之抗體及其用途
MA41842A (fr) 2015-03-31 2018-02-06 Oblique Therapeutics Ab Nouveaux procédés de sélection d'épitope
EP3303386B1 (en) 2015-06-05 2024-08-28 Genentech, Inc. Anti-tau antibodies and methods of use
CN107849105B (zh) 2015-07-06 2021-09-17 Ucb生物制药有限责任公司 Tau结合抗体
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
PL3452507T3 (pl) 2016-05-02 2023-01-09 Prothena Biosciences Limited Immunoterapia tau
CN109219615B (zh) * 2016-05-02 2022-12-09 普罗塞纳生物科学有限公司 识别tau的抗体
EP3452509A1 (en) * 2016-05-02 2019-03-13 Prothena Biosciences Limited Antibodies recognizing tau
TW202413340A (zh) 2016-07-12 2024-04-01 美商銳新醫藥公司 作為異位shp2抑制劑之2,5-雙取代型3-甲基吡嗪及2,5,6-三取代型3-甲基吡嗪
RU2760875C1 (ru) 2016-07-12 2021-12-01 Х. Лундбекк А/С Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения
JOP20170154B1 (ar) * 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
US10988529B2 (en) 2016-08-09 2021-04-27 Eli Lilly And Company Combination therapy
GB201614884D0 (en) * 2016-09-01 2016-10-19 Oblique Therapeutics Ab Method
CN110248959B (zh) 2016-12-07 2023-06-30 基因泰克公司 抗tau抗体和使用方法
AU2017373889B2 (en) 2016-12-07 2025-01-02 Ac Immune Sa Anti-Tau antibodies and methods of use
EP3565836A1 (en) 2017-01-04 2019-11-13 H. Lundbeck A/S Antibodies specific for hyperphosphorylated tau for the treatment of ocular diseases
RU2019126455A (ru) 2017-01-23 2021-02-24 Революшн Медсинз, Инк. Пиридиновые соединения в качестве аллостерических ингибиторов shp2
SG11201906209SA (en) 2017-01-23 2019-08-27 Revolution Medicines Inc Bicyclic compounds as allosteric shp2 inhibitors
KR20190134997A (ko) 2017-02-17 2019-12-05 데날리 테라퓨틱스 인크. 항-tau 항체 및 이의 사용 방법
CA3055758A1 (en) 2017-03-28 2018-10-04 Genentech, Inc. Methods of treating neurodegenerative diseases
CN110881274B (zh) * 2017-05-02 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
EP3678703A1 (en) 2017-09-07 2020-07-15 Revolution Medicines, Inc. Shp2 inhibitor compositions and methods for treating cancer
JP2020536881A (ja) 2017-10-12 2020-12-17 レヴォリューション・メディスンズ,インコーポレイテッド アロステリックshp2阻害剤としてのピリジン、ピラジンおよびトリアジン化合物
TWI750419B (zh) 2017-10-16 2021-12-21 日商衛材R&D企管股份有限公司 抗tau抗體及其用途
KR102710762B1 (ko) 2017-10-25 2024-09-25 얀센 파마슈티칼즈, 인코포레이티드 인산화 타우 펩티드의 조성물 및 이의 용도
RU2020123241A (ru) 2017-12-15 2022-01-17 Революшн Медсинз, Инк. Полициклические соединения в качестве аллостерических ингибиторов shp2
EP3784274A1 (en) * 2018-04-27 2021-03-03 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
CA3107788A1 (en) 2018-07-31 2020-02-06 Eli Lilly And Company Combination of anti-tau antibody and oga inhibitor for treatment of diseases characterized by aberrant tau aggregation
JP7681316B2 (ja) * 2019-02-08 2025-05-22 プロセナ バイオサイエンシーズ リミテッド タウを認識する抗体
KR20210125048A (ko) 2019-02-08 2021-10-15 에이씨 이뮨 에스.에이. 인산화 타우 펩티드 백신의 안전한 투여 방법
AU2020231366A1 (en) 2019-03-03 2021-08-12 Prothena Biosciences Limited Antibodies recognizing tau
KR102509648B1 (ko) 2019-08-06 2023-03-15 아프리노이아 테라퓨틱스 리미티드 병리학적 타우 종에 결합하는 항체 및 이의 용도
BR112022023366A2 (pt) 2020-05-19 2023-05-02 Othair Prothena Ltd Vacina com múltiplos epítopos para o tratamento de mal de alzheimer
KR20230080397A (ko) 2020-08-07 2023-06-07 오타이르 프로테나 리미티드 알츠하이머 질환을 치료하기 위한 멀티에피토프 백신
CN113254929B (zh) * 2021-05-21 2023-11-07 昆山翦统智能科技有限公司 一种企业远程智能服务的免疫计算与决策方法及系统
MX2024002295A (es) 2021-08-27 2024-03-07 Genentech Inc Metodos para tratar las patologias de tau.
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
EP4494141A1 (en) 2022-03-14 2025-01-22 Genentech, Inc. Predicting neurodegenerative diseases based on speech analyses
WO2023250326A1 (en) 2022-06-21 2023-12-28 Genentech, Inc. Detecting longitudinal progression of alzheimer's disease (ad) based on speech analyses
KR20250069606A (ko) 2022-09-15 2025-05-19 보이저 테라퓨틱스, 인크. 타우 결합 화합물
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0656946B2 (en) 1992-08-21 2010-03-31 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
WO1994012629A1 (en) 1992-12-02 1994-06-09 Baylor College Of Medicine Episomal vectors for gene therapy
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
DE69318420T2 (de) 1992-12-14 1999-01-28 Naamloze Vennootschap Innogenetics S.A., Gent Monoklonale antikörper gegen das mikrotubulusassoziierte tauprotein,hybridomen, die diese antikörper sezernieren, antigenerkennung durch diese monoklonalen antikörper und deren verwendung
EP0735893B1 (en) 1993-09-14 2008-11-26 Pharmexa Inc. Pan dr-binding peptides for enhancement of the immune response
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
EP1005368B1 (en) 1997-03-10 2009-09-02 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
CA2361492A1 (en) 1999-02-05 2000-08-10 Samsung Electronics Co., Ltd. Image texture retrieving method and apparatus thereof
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
JP4393382B2 (ja) 2002-08-14 2010-01-06 三菱化学株式会社 中枢性タウ蛋白質特異的抗体
MXPA05005481A (es) 2002-11-29 2005-07-25 Boehringer Ingelheim Pharma Nuevos genes de la fosfotransferasa de neomicina y procedimiento para la seleccion de celulas recombinantes de produccion elevada.
US7847146B2 (en) * 2003-03-28 2010-12-07 Baylor College Of Medicine Model for neurodegenerative disorders
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
US20050132424A1 (en) * 2003-10-21 2005-06-16 Envivo Pharmaceuticals, Inc. Transgenic flies expressing Abeta42-Dutch
US7910100B2 (en) * 2004-10-01 2011-03-22 Max-Planck-Gesellschaft zur Forderung der Wissen Antibodies directed to the mammalian EAG1 ion channel protein
PT1820022E (pt) 2004-11-10 2009-08-05 Boehringer Ingelheim Pharma Utilização de análise por citometria de fluxo para optimizar estratégias de conservação de bancos de células cho
AU2005318171B2 (en) 2004-12-20 2011-09-29 Crucell Holland B.V. Binding molecules capable of neutralizing West Nile virus and uses thereof
ATE500276T1 (de) 2004-12-30 2011-03-15 Us Gov Health & Human Serv Humanisierte col-1-antikörper mit substituierten resten am gerüst, und deren anwendung
CA2621502A1 (en) * 2005-09-07 2007-03-15 Medimmune, Inc. Toxin conjugated eph receptor antibodies
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
WO2007149293A2 (en) * 2006-06-16 2007-12-27 Envivo Pharmaceutical, Inc. Transgenic flies expressing tau and amyloid precursor fragment
WO2007147213A1 (en) 2006-06-22 2007-12-27 Walter And Eliza Hall Institute Of Medical Research Structure of the insulin receptor ectodomain
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
US20100216703A1 (en) * 2006-08-14 2010-08-26 The Regents Of The University Of California Inhibitors of PDE4 and Methods of Use
CN103172743B (zh) * 2006-12-01 2015-04-08 梅达雷克斯有限责任公司 结合cd22的人抗体及其用途
DK3067066T3 (da) 2007-02-23 2019-05-20 Prothena Biosciences Ltd Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom
WO2008107388A1 (en) 2007-03-02 2008-09-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Improvement of protein production
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
JP2009056790A (ja) 2007-09-03 2009-03-19 Takao Otogawa ファイル用ポケット
BRPI0817255A2 (pt) * 2007-09-26 2017-06-06 Amgen Inc proteínas de ligação a antígeno de fator de crescimento tipo fator de crescimento epidermal de ligação à heparina.
US9272030B2 (en) 2007-10-17 2016-03-01 Janssen Sciences Ireland Uc Use of tau to monitor immunotherapy
CA2705292C (en) * 2007-11-13 2016-06-21 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against tl1a
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
JP2010014691A (ja) * 2008-06-20 2010-01-21 Igaku Seibutsugaku Kenkyusho:Kk 腹水中のメソテリン及び/又は巨核球増強因子を検出するための方法、キット、試薬及び装置
NZ591471A (en) * 2008-08-18 2012-08-31 Pfizer Antibodies to ccr2
US9605054B2 (en) * 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
KR20160005143A (ko) 2009-05-13 2016-01-13 젠자임 코포레이션 항-인간 cd52 면역글루불린
EP4218794A3 (en) * 2009-06-10 2023-09-13 New York University Immunological targeting of pathological tau proteins
US20110045534A1 (en) * 2009-08-20 2011-02-24 Cell Signaling Technology, Inc. Nucleic Acid Cassette For Producing Recombinant Antibodies
WO2011026031A1 (en) 2009-08-28 2011-03-03 The Board Of Regents Of The University Of Texas System Antibodies that bind tau oligomers
WO2011053565A2 (en) 2009-10-29 2011-05-05 Biomedical Sciences Research Centre "Alexander Fleming" Compositions and methods for detecting a tauopathy
JP2013514992A (ja) 2009-12-18 2013-05-02 アムジェン インコーポレイテッド Wise結合剤およびエピトープ
CN102711812B (zh) 2010-01-08 2014-07-16 国立大学法人京都大学 Tau蛋白病治疗用疫苗
MX2012009215A (es) 2010-02-23 2012-11-23 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
ITRM20100320A1 (it) * 2010-06-11 2011-12-11 Consiglio Nazionale Ricerche Metodo per la diagnostica e il trattamento delle taupatie
US20120023911A1 (en) 2010-07-28 2012-02-02 Gm Global Technology Operations, Inc. Detection of exhaust particulate filter substrate failure
LT2627672T (lt) * 2010-10-11 2018-12-10 Biogen International Neuroscience Gmbh Žmogaus antikūnai prieš tau baltymą
AR084210A1 (es) * 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
JP2014511174A (ja) * 2011-02-07 2014-05-15 ネオトープ バイオサイエンシーズ リミテッド Apoe免疫療法
EP2701743A4 (en) 2011-04-27 2015-08-19 Univ Northwestern FOR PATHOLOGICAL TAU-DIMERE AND PREAFIBRILLARY PATHOLOGICAL TAU-OLIGOMER SELECTIVE ANTIBODIES AND THEIR USES IN THE APPLICATION, DIAGNOSIS AND MONITORING OF TAUOPATHIES
GB201109238D0 (en) 2011-06-01 2011-07-13 Antitope Ltd Antibodies
GB201111361D0 (en) * 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
CA2845884A1 (en) * 2011-08-22 2013-02-28 Cangene Corporation Clostridium difficile antibodies
SMT201800109T1 (it) 2011-09-19 2018-05-02 Axon Neuroscience Se Terapia a base di proteine e diagnosi di una patologia mediata da tau nella malattia di alzheimer
TW201326209A (zh) 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd 具有促進抗原清除之FcRn結合域的治療性抗原結合分子
JP6358953B2 (ja) 2011-10-07 2018-07-18 エーシー イミューン エス.エー. タウを認識するホスホ特異的抗体
LT2831113T (lt) 2012-03-28 2018-06-25 Sanofi Antikūnai prieš bradikinino b1 receptoriaus ligandus
RU2644242C2 (ru) 2012-04-05 2018-02-08 Ац Иммуне С.А. Гуманизированное тау-антитело
CA2868327A1 (en) 2012-04-18 2013-10-24 E. I. Du Pont De Nemours And Company Multilayered sheet
DE102012211455A1 (de) 2012-07-02 2014-01-02 Wobben Properties Gmbh Handhabungsvorrichtung zum Handhaben einer Rotorblattform zum Fertigen eines Rotorblattes einer Windenergieanlage
WO2014008404A1 (en) * 2012-07-03 2014-01-09 Washington University Antibodies to tau
JP6290212B2 (ja) 2012-08-16 2018-03-07 アイピエリアン,インコーポレイティド タウオパチーの処置方法
US20140056901A1 (en) 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
WO2014059442A2 (en) 2012-10-12 2014-04-17 Arizona Board Agents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
JP6284548B2 (ja) 2012-12-21 2018-02-28 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. ヒト抗タウ抗体
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
US9364191B2 (en) 2013-02-11 2016-06-14 University Of Rochester Method and apparatus of spectral differential phase-contrast cone-beam CT and hybrid cone-beam CT
JP6674888B2 (ja) 2013-03-13 2020-04-01 プロセナ バイオサイエンシーズ リミテッド タウ免疫療法
EP3418430B1 (en) 2013-03-15 2023-03-29 The Trustees of the University of Pennsylvania Blood biomarkers that predict persistent cognitive dysfunction after concussion
US9688747B2 (en) 2013-03-15 2017-06-27 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
CN105658672A (zh) 2013-08-22 2016-06-08 阿塞勒隆制药公司 TGF-β受体II型变体及其用途
JP6629201B2 (ja) 2013-11-27 2020-01-15 アイピエリアン,インコーポレイティド タウオパチーの処置方法
JP2017505756A (ja) 2013-12-13 2017-02-23 ザ ジェネラル ホスピタル コーポレイション 可溶性高分子量(hmw)タウ種およびその用途
KR102357961B1 (ko) * 2013-12-17 2022-02-08 제넨테크, 인크. 항-cd3 항체 및 이의 사용 방법
US9629801B2 (en) 2014-01-10 2017-04-25 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
US20150253341A1 (en) 2014-02-10 2015-09-10 Merck Sharp & Dohme Corp. Quantification of tau in biological samples by immunoaffinity enrichment and mass spectrometry
CA2952745A1 (en) 2014-06-26 2015-12-30 Janssen Vaccines & Prevention B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
TW202136296A (zh) 2014-06-27 2021-10-01 美商C2N醫療診斷有限責任公司 人類化抗-tau抗體
PT3221349T (pt) 2014-11-19 2021-01-21 Axon Neuroscience Se Anticorpos tau humanizados na doença de alzheimer
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
WO2016137950A1 (en) 2015-02-24 2016-09-01 Rpeptide, Llc Anti-tau antibodies
EP3303386B1 (en) 2015-06-05 2024-08-28 Genentech, Inc. Anti-tau antibodies and methods of use
US20200030445A1 (en) 2015-06-12 2020-01-30 C2N Diagnostics, Llc Stable formulations of humanized anti-tau antibody
CN107849105B (zh) 2015-07-06 2021-09-17 Ucb生物制药有限责任公司 Tau结合抗体
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
US11327080B2 (en) 2015-07-21 2022-05-10 BioArctic Neruoscience AB Method for treatment of traumatic brain injury targeting aggregated peptides
JP7725185B2 (ja) 2015-10-06 2025-08-19 アレクトル エルエルシー 抗trem2抗体及びその使用方法
CN109219615B (zh) 2016-05-02 2022-12-09 普罗塞纳生物科学有限公司 识别tau的抗体
EP3452509A1 (en) 2016-05-02 2019-03-13 Prothena Biosciences Limited Antibodies recognizing tau
PL3452507T3 (pl) 2016-05-02 2023-01-09 Prothena Biosciences Limited Immunoterapia tau
WO2018085653A1 (en) 2016-11-04 2018-05-11 The Regents Of The University Of California Compositions targeting 3-repeat tau for the treatment of neurodegenerative disorders, and methods for making and using them
AU2017373889B2 (en) 2016-12-07 2025-01-02 Ac Immune Sa Anti-Tau antibodies and methods of use
CN110248959B (zh) 2016-12-07 2023-06-30 基因泰克公司 抗tau抗体和使用方法
KR20190134997A (ko) 2017-02-17 2019-12-05 데날리 테라퓨틱스 인크. 항-tau 항체 및 이의 사용 방법
WO2018156250A1 (en) 2017-02-21 2018-08-30 Remd Biotherapeutics, Inc. Cancer treatment using antibodies that bind cytotoxic t-lymphocyte antigen-4 (ctla-4)
JOP20180021A1 (ar) 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
CN110418804A (zh) 2017-03-28 2019-11-05 扬森疫苗与预防公司 与tau特异性地结合的结合分子
CA3055758A1 (en) 2017-03-28 2018-10-04 Genentech, Inc. Methods of treating neurodegenerative diseases
CN110881274B (zh) 2017-05-02 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
CN110770253A (zh) 2017-06-16 2020-02-07 百时美施贵宝公司 用于治疗tau蛋白病的组合物和方法
TWI750419B (zh) 2017-10-16 2021-12-21 日商衛材R&D企管股份有限公司 抗tau抗體及其用途
AU2018364630A1 (en) 2017-11-09 2020-05-21 Pinteon Therapeutics Inc. Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
SG11202004904XA (en) 2017-12-04 2020-06-29 Janssen Vaccines & Prevention Bv Binding molecules that specifically bind to tau
CA3094934A1 (en) 2018-03-23 2019-09-26 AbbVie Deutschland GmbH & Co. KG Stable aqueous anti-tau antibody formulations
MX2020009991A (es) 2018-03-28 2020-10-14 Axon Neuroscience Se Metodos basados en anticuerpos para detectar y tratar la enfermedad de alzheimer.
EP3784274A1 (en) 2018-04-27 2021-03-03 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
WO2020097561A1 (en) 2018-11-08 2020-05-14 Prothena Biosciences Limited Antibodies recognizing tau
WO2020096608A1 (en) 2018-11-08 2020-05-14 Prothena Biosciences Limited Antibodies recognizing tau
WO2020106598A1 (en) 2018-11-19 2020-05-28 The Board Of Regents Of The University Of Texas System Tau peptide antigens and antibodies binding thereto for the treatment of tauopathies
JP7681316B2 (ja) 2019-02-08 2025-05-22 プロセナ バイオサイエンシーズ リミテッド タウを認識する抗体
AU2020231366A1 (en) 2019-03-03 2021-08-12 Prothena Biosciences Limited Antibodies recognizing tau
EP3947446A1 (en) 2019-03-25 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of taupathy disorders by targeting new tau species
CN114430744B (zh) 2019-07-15 2024-06-21 阿德尔公司 抗Tau抗体及其用途

Similar Documents

Publication Publication Date Title
JP2016512551A5 (OSRAM)
PE20200862A1 (es) Anticuerpos anti-trem2 y metodos relacionados
JP2012530496A5 (OSRAM)
JP2017052784A5 (OSRAM)
JP2018183173A5 (OSRAM)
JP2013545455A5 (OSRAM)
JP2011514150A5 (OSRAM)
JP2017526370A5 (OSRAM)
JP2014534242A5 (OSRAM)
JP2015504306A5 (OSRAM)
JP2010022372A5 (OSRAM)
IL262726B1 (en) Antibodies recognizing tau
RU2016100892A (ru) Антитела против tweakr и их применение
JP2020511947A5 (OSRAM)
JP2016511277A5 (OSRAM)
JP2018510636A5 (OSRAM)
JP2019525724A5 (OSRAM)
JP2015533853A5 (OSRAM)
JP2018510617A5 (OSRAM)
JP2015533795A5 (OSRAM)
JP2010526028A5 (OSRAM)
JP2011046732A5 (OSRAM)
RU2017119185A (ru) Антитела против fgfr2/3 и способы их применения
JP2016505546A5 (OSRAM)
RU2015136078A (ru) Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний